Chad Cannon

Jul 23, 2024 | ajmc.com | Sophia Z. Humphreys |Chad Cannon |Eric Tichy |Susan Peppers

OpinionVideoJuly 23, 2024Author(s):,The expert panel discusses the greater potential for private label biosimilars. Video content above is prompted by the following questions:Some healthcare companies are investigating the potential for private label biosimilars, including products like adalimumab. What is the value of offering a private label biosimilar to patients? What are some of the challenges that may arise?